NanoViricides Advances First Oral Ebola Drug Trial as DRC Outbreak Worsens

Kinshasa, Tuesday, 8 September 2026.
NanoViricides has registered a Phase II trial in the DRC for its oral gummy Ebola candidate, offering an easily deliverable treatment during an expanding outbreak with a 48% mortality rate.